These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 35973974

  • 1. Characterisation of the urinary steroid profile of patients with nonfunctioning adrenal incidentalomas: A matched controlled cross-sectional study.
    Araujo-Castro M, Casals G, Hanzu FA, Pascual-Corrales E, García Cano AM, Lanza VF, Luis Del Rey Mejías Á, Marchan M, Escobar-Morreale HF, Valderrabano P.
    Clin Endocrinol (Oxf); 2023 Feb; 98(2):165-176. PubMed ID: 35973974
    [Abstract] [Full Text] [Related]

  • 2. Is the 1mg-dexamethasone suppression test a precise marker of glucocorticoid excess and cardiometabolic risk in patients with adrenal incidentalomas?
    Araujo-Castro M, Hanzu FA, Pascual-Corrales E, García Cano AM, Marchan M, Escobar-Morreale HF, Valderrabano P, Casals G.
    Endocrine; 2023 Oct; 82(1):161-170. PubMed ID: 37351760
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Body Composition in Patients With and Without Adrenal Tumors and Without Overt Hypersecretory Syndromes.
    Araujo-Castro M, Pascual-Corrales E, García Cano AM, Marchan M, Casals G, Hanzu FA, Gomez-Bermejo MÁ, Escobar Morreale HF, Valderrabano P.
    Endocr Pract; 2023 Feb; 29(2):110-118. PubMed ID: 36455692
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences?
    Araujo-Castro M, Robles Lázaro C, Parra Ramírez P, Cuesta Hernández M, Sampedro Núñez MA, Marazuela M.
    Endocrine; 2019 Dec; 66(3):650-659. PubMed ID: 31473918
    [Abstract] [Full Text] [Related]

  • 6. Adrenal incidentaloma: Do patients with apparently nonfunctioning mass or autonomous cortisol secretion have similar or different clinical and metabolic features?
    Rebelo JFD, Costa JM, Junqueira FD, Fonseca AO, de Almeida ABABS, Moraes AB, Vieira Neto L.
    Clin Endocrinol (Oxf); 2023 May; 98(5):662-669. PubMed ID: 36514987
    [Abstract] [Full Text] [Related]

  • 7. Nonfunctioning Adrenal Incidentalomas are not Clinically Silent: A Longitudinal Cohort Study.
    Kim JH, Kim MJ, Lee JH, Yoon JW, Shin CS.
    Endocr Pract; 2020 Dec; 26(12):1406-1415. PubMed ID: 33471732
    [Abstract] [Full Text] [Related]

  • 8. Cardiometabolic profile and urinary metabolomic alterations in non-functioning adrenal incidentalomas: A review.
    Araujo-Castro M.
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):693-701. PubMed ID: 35451056
    [Abstract] [Full Text] [Related]

  • 9. Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study.
    Falcetta P, Orsolini F, Benelli E, Agretti P, Vitti P, Di Cosmo C, Tonacchera M.
    Endocrine; 2021 Jan; 71(1):178-188. PubMed ID: 32915435
    [Abstract] [Full Text] [Related]

  • 10. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion.
    Androulakis II, Kaltsas GA, Kollias GE, Markou AC, Gouli AK, Thomas DA, Alexandraki KI, Papamichael CM, Hadjidakis DJ, Piaditis GP.
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2754-62. PubMed ID: 24712565
    [Abstract] [Full Text] [Related]

  • 11. Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion.
    Araujo-Castro M, Mínguez Ojeda C, Sánchez Ramírez MN, Gómez Dos Santos V, Pascual-Corrrales E, Fernández-Argüeso M.
    Endocrine; 2022 Oct; 78(1):142-150. PubMed ID: 35751779
    [Abstract] [Full Text] [Related]

  • 12. Accuracy of the dexamethasone suppression test for the prediction of autonomous cortisol secretion-related comorbidities in adrenal incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2021 Dec; 20(4):735-744. PubMed ID: 34273083
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and incidence of type 2 diabetes mellitus in patients with adrenal incidentalomas: a study of 709 cases.
    Brox-Torrecilla N, García Cano AM, Valderrábano P, Quintero Tobar A, Escobar-Morreale HF, Araujo-Castro M.
    Endocrine; 2023 Sep; 81(3):484-491. PubMed ID: 37212980
    [Abstract] [Full Text] [Related]

  • 14. Predictors of Tumour Growth and Autonomous Cortisol Secretion Development during Follow-Up in Non-Functioning Adrenal Incidentalomas.
    Araujo-Castro M, Parra Ramírez P, Robles Lázaro C, García Centeno R, Gracia Gimeno P, Fernández-Ladreda MT, Sampedro Núñez MA, Marazuela M, Escobar-Morreale HF, Valderrabano P.
    J Clin Med; 2021 Nov 25; 10(23):. PubMed ID: 34884211
    [Abstract] [Full Text] [Related]

  • 15. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk.
    Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, Pelusi C, Gambineri A, Altieri P, Mosconi C, Balacchi C, Golfieri R, Cosentino ER, Borghi C, Vicennati V, Pasquali R, Pagotto U.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5519-5528. PubMed ID: 31381072
    [Abstract] [Full Text] [Related]

  • 16. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
    Herrera-Martínez AD, Román ÁR, Corrales EP, Idrobo C, Ramírez PP, Rojas PM, Lázaro CR, Araujo-Castro M.
    Front Endocrinol (Lausanne); 2023 Nov 01; 14():1335202. PubMed ID: 38264281
    [Abstract] [Full Text] [Related]

  • 17. Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism.
    Nakao H, Yokomoto-Umakoshi M, Nakatani K, Umakoshi H, Ogata M, Fukumoto T, Kaneko H, Iwahashi N, Fujita M, Ogasawara T, Matsuda Y, Sakamoto R, Izumi Y, Bamba T, Ogawa Y.
    EBioMedicine; 2023 Sep 01; 95():104733. PubMed ID: 37543511
    [Abstract] [Full Text] [Related]

  • 18. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up.
    Papanastasiou L, Alexandraki KI, Androulakis II, Fountoulakis S, Kounadi T, Markou A, Tsiavos V, Samara C, Papaioannou TG, Piaditis G, Kaltsas G.
    Clin Endocrinol (Oxf); 2017 Apr 01; 86(4):488-498. PubMed ID: 27992961
    [Abstract] [Full Text] [Related]

  • 19. Diabetes Mellitus in Non-Functioning Adrenal Incidentalomas: Analysis of the Mild Autonomous Cortisol Secretion (MACS) Impact on Glucose Profile.
    Trandafir AI, Ghemigian A, Ciobica ML, Nistor C, Gurzun MM, Nistor TVI, Petrova E, Carsote M.
    Biomedicines; 2024 Jul 18; 12(7):. PubMed ID: 39062179
    [Abstract] [Full Text] [Related]

  • 20. Predictive model for autonomous cortisol secretion development in non-functioning adrenal incidentalomas.
    Araujo-Castro M, García Cano AM, Escobar-Morreale HF, Valderrabano P.
    Hormones (Athens); 2023 Mar 18; 22(1):51-59. PubMed ID: 36279032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.